The results of the study showed that SGLT2 inhibitor dapagliflozyn modified the levels of apelin depending on the phenotype of HF, exerting most meaningful effect in patients with HFpEF rather than HFmrEF or HFrEF. The gene discussed is SLC5A2; the disease is hydrops fetalis.